Qiagen and AstraZeneca, Nature Publishing and Cold Spring Harbor Laboratory Press, and AVI BioPharma and Medtronic | GenomeWeb

Qiagen Sells Synthetic DNA Business, Inks siRNA Supply Deal with AstraZeneca

Qiagen announced this week that it has sold its synthetic DNA business to a management team previously employed by the company and which operated parts of this business. Qiagen said that it will retain all rights to its siRNA business.

Under the terms of the deal, Qiagen will receive $24.3 million, $17.8 million of which is in cash with the remainder in a promissory note. Qiagen will also retain a 16 percent stake in the business, which will be named Operon Biotechnologies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.